Jun 22, 2026
Eli Lilly stock (LLY): is it a buy at 30x as the GLP-1 leader, with orforglipron and the patent cliff ahead
LLY deep dive: Hold at ~30x fwd P/E. Bear/base/bull across 6 months, 1 year, 3 years, and 5 years on tirzepatide, Foundayo, retatrutide, and the 2036 patent cliff.
